RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, a...
RespireRx Pharmaceuticals reported revenue of $0 for fiscal year 2022, and net income of -$3.97 million. In Q3 2023 (the quarter ended September 30, 2023) revenue was $0. Its market capitalization was $849,134 as of January 29, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2022; market data as of January 29, 2026.
No profile data available.